MangoGen Pharma Inc. is a biotech company with a mission to develop novel approaches to deliver specific genes to treat and accelerate wound healing. Proof-of-concept data has shown that our approach can accelerate wound healing (re-endothelialization) around a stent site, reducing the risk of developing in-stent re-stenosis. The potential outcomes of this approach are improved patient outcome, and significant socio-economic savings.
The MangoGen team is dedicated to developing and producing a novel stent, and wound healing creams/gels and sutures.
If you are interested in investment opportunities, please contact:
Paul Plested D.Phil. (Oxford)
+1 514-800-6872 x101
For recent news about MangoGen go to NEWS